NASDAQ · RPRX
Healthcare · Biotechnology
$63.96
Up+$0.08 (+0.13%)
Updated Sep 7, 2026, 11:31 AM
SID Score
7.4/10
Composite research score
Smart Money
58/100
Neutral
Price performance
1M range · 0 trading sessions · Daily adjusted prices
RPRX does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning RPRX.
RPRX research
Company profile and research snapshot.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 7, 2026 | JP Morgan | Overweight | — |
| Jul 13, 2026 | TD Cowen | Buy | — |
| May 7, 2026 | JP Morgan | Overweight | — |
| May 7, 2026 | Citigroup | Buy | — |
| Apr 21, 2026 | UBS | Buy | — |
No generated briefing is available yet.
Yahoo · Sep 1, 2026
On August 12, Royalty Pharma (NASDAQ:RPRX) agreed to pay Zealand Pharma $100 million for the rights to future royalties on rusfertide, an experimental treatment for a rare blood disorder called polycythemia vera. It is Royalty Pharma’s second collaboration with Zealand, and it arrives just as rusfertide awaits a decision from the FDA. For a company […]
SeekingAlpha · Aug 26, 2026
Royalty Pharma shows strong execution and upside catalysts as it shifts to higher-IRR development assets and still trades at a discount. Click for more on RPRX.
SeekingAlpha · Aug 26, 2026
Royalty Pharma (RPRX) buy thesis: 2Q26 royalty growth, 95% margins, and higher 2026 guidance signal strong cash flow compounding. See more here.
Yahoo · Aug 25, 2026
Merck shares rose on growing confidence in its cancer pipeline, while Royalty Pharma hit a record high as Ziihera’s FDA approval strengthened its royalty opportunity.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning RPRX.
